These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 36583180)

  • 1. Corrigendum re "Impact of Body Mass Index on Survival Outcomes for Patients with Metastatic Renal Cell Carcinoma in the Immuno-oncology Era: A Systematic Review and Meta-analysis" [Eur Urol Open Sci 2022;39:62-71].
    Takemura K; Yonekura S; Downey LE; Evangelopoulos D; Heng DYC
    Eur Urol Open Sci; 2023 Feb; 48():17. PubMed ID: 36583180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Corrigendum re "Hypofractionated Postoperative Radiotherapy for Prostate Cancer: Is the Field Ready Yet?" [Eur Urol Open Sci 2020;22:9-16].
    Mahase S; Nagar H
    Eur Urol Open Sci; 2022 Oct; 44():52-53. PubMed ID: 36093321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Corrigendum re "Prostate-specific Membrane Antigen Positron Emission Tomography, Not Conventional Imaging, Should Be Performed for Primary Staging of High-risk Prostate Cancer" [Eur Urol Open Sci 2021;34:17-18].
    Ceci F; Musi G; De Cobelli O
    Eur Urol Open Sci; 2022 May; 39():47. PubMed ID: 35403012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Corrigendum to "Rectal Perforation During Pelvic Surgery" [Eur Urol Open Sci 44 (2022) 54-59].
    Rocco B; Gaia G; Assumma S; Calcagnile T; Sangalli M; Terzoni S; Eissa A; Bozzini G; De Concilio B; Celia A; Micali S; Sighinolfi MC
    Eur Urol Open Sci; 2023 Mar; 49():10. PubMed ID: 36874597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Corrigendum to "RPN (Radius, Position of tumour, iNvasion of renal sinus) Classification and Nephrometry Scoring System: An Internationally Developed Clinical Classification To Describe the Surgical Difficulty for Renal Masses for Which Robotic Partial Nephrectomy Is Planned" [Eur. Urol. Open Sci. 54 (2023) 33-42].
    Agarwal DK; Mulholland C; Koye DN; Sathianathen N; Yao H; Dundee P; Moon D; Furrer M; Giudice C; Wang W; Simpson JA; Kearsley J; Norris B; Zargar H; Pan HYC; Mottrie A; Fuller A; Mottaran A; Challacombe B; Kua B; Metcalfe C; Wagner C; Dubey D; Gomez Sancha F; Bruyère F; Gautam G; Pooleri GK; Bozzini G; Lau H; Thyer I; Teoh J; Vass J; Vivian J; McDermott K; Winter M; Ragavan N; Campbell N; Harke NN; Richard PO; Teloken P; Dekuyper P; Sutherland P; Ahlawat R; Nair R; Pemberton R; Catterwell R; Oomen RJA; Weston R; Moritz R; Krishnappa RS; Leslie S; Van Appledorn S; Yuvaraja TB; Meert T; Dujardin T; Gross T; Walton T; Huang WC; Caumartin Y; Agarwal A; Lawrentschuk N; Corcoran NM
    Eur Urol Open Sci; 2024 May; 63():2-3. PubMed ID: 38523653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Corrigendum to "Clinical Trial Protocol: Developing an Image Classification Algorithm for Prostate Cancer Diagnosis on Three-dimensional Multiparametric Transrectal Ultrasound" [Eur. Urol. Open Sci. 49 (2023) 32-43].
    Jager A; Postema AW; Mischi M; Wijkstra H; Beerlage HP; Oddens JR
    Eur Urol Open Sci; 2023 Aug; 54():65. PubMed ID: 37397278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Body Mass Index on Survival Outcomes of Patients with Metastatic Renal Cell Carcinoma in the Immuno-oncology Era: A Systematic Review and Meta-analysis.
    Takemura K; Yonekura S; Downey LE; Evangelopoulos D; Heng DYC
    Eur Urol Open Sci; 2022 May; 39():62-71. PubMed ID: 35528786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Re: Keiichiro Mori, Mohammad Abufaraj, Hadi Mostafaei, et al. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.10.006: Clinical Activity of Immune Checkpoint Inhibitors: Is the Host the Answer?
    Noel J; Huillard O; Goldwasser F
    Eur Urol; 2021 Apr; 79(4):e112. PubMed ID: 33518379
    [No Abstract]   [Full Text] [Related]  

  • 9. Reply to Johanna Noel, Olivier Huillard, and Francois Goldwasser's Letter to the Editor re: Keiichiro Mori, Mohammad Abufaraj, Hadi Mostafaei, et al. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.10.006. Clinical Activity of Immune Checkpoint Inhibitors: Is the Host the Answer?
    Mori K; Schmidinger M; Egawa S; Gust KM; Shariat SF
    Eur Urol; 2021 Apr; 79(4):e113-e114. PubMed ID: 33487477
    [No Abstract]   [Full Text] [Related]  

  • 10. Re: Rohann J.M. Correa, Alexander V. Louie, Nicholas G. Zaorsky, et al. The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2019.06.002.
    Montorsi F; Larcher A; Capitanio U
    Eur Urol Focus; 2021 Mar; 7(2):406. PubMed ID: 31564640
    [No Abstract]   [Full Text] [Related]  

  • 11. Corrigendum to "Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma" [Eur Urol 2023].
    Ernst MS; Navani V; Wells JC; Donskov F; Basappa N; Labaki C; Pal SK; Meza L; Wood LA; Ernst DS; Szabados B; McKay RR; Parnis F; Suarez C; Yuasa T; Lalani AK; Alva A; Bjarnason GA; Choueiri TK; Heng DYC
    Eur Urol; 2023 Jun; 83(6):e166-e167. PubMed ID: 36967358
    [No Abstract]   [Full Text] [Related]  

  • 12. Re: Christopher J.D. Wallis, Zachary Klaassen, Bimal Bhindi, et al. Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta-analysis. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2017.10.002.
    Vale C; Fisher D; Tierney J; White I; Sydes M; Carpenter J
    Eur Urol; 2018 Mar; 73(3):e49-e50. PubMed ID: 29233663
    [No Abstract]   [Full Text] [Related]  

  • 13. Re: Bimal Bhindi, E. Jason Abel, Laurence Albiges, et al. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma. Eur Urol 2019;75:111-28: Cytoreductive Nephrectomy in the Targeted Therapy Era: This is Not the End.
    Massari F; Di Nunno V; Santoni M; Gatto L; Mollica V; Porta C
    Eur Urol Oncol; 2019 Sep; 2(5):603-604. PubMed ID: 31411982
    [No Abstract]   [Full Text] [Related]  

  • 14. Corrigendum to "Is there a role for perfusion imaging in assessing treatment response following ablative therapy of small renal masses-A systematic review" [Eur. J. Radiol. Open 5 (2018) 102-107].
    Withey SJ; Gariani J; Reddy K; Prezzi D; Kelly-Morland C; Ilyas S; Adam A; Goh V
    Eur J Radiol Open; 2019; 6():e1. PubMed ID: 31886320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Re: Bimal Bhindi, Jeffrey Graham, J. Connor Wells, et al. Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.04.038: Cytoreductive Nephrectomy: To Whom and When?
    Mollica V; Rizzo A; Massari F
    Eur Urol Oncol; 2020 Aug; 3(4):559-560. PubMed ID: 32553708
    [No Abstract]   [Full Text] [Related]  

  • 16. Re: Michal Sarfaty, Moshe Leshno, Noa Gordon, et al. Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2017.07.041: Second-line Treatment in Metastatic Renal Cell Carcinoma. Can Immunotherapy Be Considered a Cost-effective Treatment?
    Giuliani J; Bonetti A
    Eur Urol; 2018 Mar; 73(3):e74. PubMed ID: 29097098
    [No Abstract]   [Full Text] [Related]  

  • 17. Reply to Francesco Montorsi, Alessandro Larcher, and Umberto Capitanio's Letter to the Editor re: Rohann J.M. Correa, Alexander V. Louie, Nicholas G. Zaorsky, et al. The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. Eur Urol Focus. 2019 Jun 24. pii: S2405-4569(19)30157-9. https://doi.org/10.1016/j.euf.2019.06.002. [Epub ahead of print].
    Correa RJM; Louie AV; Zaorsky NG; Lehrer EJ; Ellis R; Ponsky L; Kaplan I; Mahadevan A; Chu W; Swaminath A; Hannan R; Onishi H; Teh BS; Muacevic A; Lo SS; Staehler M; Siva S
    Eur Urol Focus; 2021 Mar; 7(2):404-405. PubMed ID: 31679868
    [No Abstract]   [Full Text] [Related]  

  • 18. Re: Keiichiro Mori, Mohammad Abufaraj, Hadi Mostafaei, et al. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis. Eur Urol 2021;79:783-92.
    Gao X; Chen G; Wei X
    Eur Urol; 2021 Dec; 80(6):e143-e144. PubMed ID: 34593263
    [No Abstract]   [Full Text] [Related]  

  • 19. Corrigendum re: "Percutaneous Nephrolithotomy Versus Retrograde Intrarenal Surgery: A Systematic Review and Meta-analysis" [Eur Urol 2015;67:125-37].
    De S; Autorino R; Kim FJ; Zargar H; Laydner H; Balsamo R; Torricelli FC; Di Palma C; Molina WR; Monga M; De Sio M
    Eur Urol; 2016 Apr; 69(4):e85. PubMed ID: 27301798
    [No Abstract]   [Full Text] [Related]  

  • 20. First-line Treatment of Metastatic Renal Cell Carcinoma in the Immuno-oncology Era: Systematic Review and Network Meta-analysis.
    Monteiro FSM; Soares A; Debiasi M; Schutz FA; Maluf FC; Bastos DA; Sasse A; Cauduro CGS; Mendes GO; Ziegelmann PK; Fay AP
    Clin Genitourin Cancer; 2020 Aug; 18(4):244-251.e4. PubMed ID: 32303427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.